Applications for San Francisco (Batch 12) extended AGAIN through September 30th, 2021!

Learn more about investing in STÄMM

Our team will get back to you soon to follow up on your inquiry.
STÄMM
Scale down to scale up
Founded
2013
Employees*
11-50
Funding to Date*
undisclosed
Website
stamm.bio
Juan “Yuyo” Llamazares, CEO
Right now, biomanufacturing is “hidden” in big facilities, but with our technology, it can be used by more people at a smaller scale and more people will see the power of biology to manufacture or to solve problems.
One of the other companies currently at IndieBio used our system to significantly increase the productivity of their process over the course of 20 days.

Biology is the best platform for manufacturing cells. It can grow and produce all kinds of biomaterials very effectively. But for humans to be able to tap into this potential, we have to build bioreactors and figure out how to scale them in order to produce the massive amounts of biomaterials we need.

Bioreactors technology is very different when you’re optimizing for one reaction at one liter versus 100,000 liters, but this is where Stämm comes in. They are reinventing the way bioreactors work by developing a modular microfluidic platform that controls all the physical parameters, such as nutrients and dissolved oxygen, in a controlled environment. Unlike traditional bioreactor systems, their microfluidic bioreactor scales by adding more modules to increase the size of the reactor.